PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences

PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences

BOSTON–(BUSINESS WIRE)–PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that members of its management team will present at the 38th Annual J.P. Morgan Healthcare Conference and other upcoming virtual conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005161/en/

PureTech’s founder and chief executive officer, Daphne Zohar, president and chief of business and strategy, Bharatt Chowrira, J.D., Ph.D., and chief innovation officer, Eric Elenko, Ph.D., will present at three upcoming conferences. (Photo: Business Wire)

PureTech’s founder and chief executive officer, Daphne Zohar, president and chief of business and strategy, Bharatt Chowrira, J.D., Ph.D., and chief innovation officer, Eric Elenko, Ph.D., will present at three upcoming conferences. (Photo: Business Wire)

38th Annual J.P. Morgan Healthcare Conference

Presenter: Daphne Zohar, founder and chief executive officer

Date: Thursday, January 14th, 2021

Time: 10:50am EST

Davy & Peel Hunt Ireland & UK Equity Conference

Presenters: Bharatt Chowrira, J.D., Ph.D., president and chief of business and strategy; Eric Elenko, Ph.D., chief innovation officer

Date: Tuesday, January 5th, 2021

Time: 1:00pm EST

WuXi Global Forum 2021 – Advancing Breakthroughs for Patients

Presenter: Daphne Zohar, founder and chief executive officer

Date: Wednesday, January 13th, 2021

Time: 12:10pm EST

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, is comprised of 24 products and product candidates, including two that have received U.S. Food and Drug Administration (FDA) clearance and European marketing authorization. All of the underlying programs and platforms that resulted in this pipeline of product candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company’s unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking statements, including statements that relate to our product candidates and approach towards addressing major diseases, future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, our expectations regarding the potential therapeutic benefits of our product candidates and those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Investors

Allison Mead Talbot

+1 617 651 3156

[email protected]

U.S. media

Adam Silverstein

+1 917 697 9313

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Software Biotechnology Pharmaceutical General Health Health Technology Other Technology Other Health

MEDIA:

Logo
Logo
Photo
Photo
PureTech’s founder and chief executive officer, Daphne Zohar, president and chief of business and strategy, Bharatt Chowrira, J.D., Ph.D., and chief innovation officer, Eric Elenko, Ph.D., will present at three upcoming conferences. (Photo: Business Wire)

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer

Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO reduced the risk of disease recurrence or death by 80%

WILMINGTON, Del.–(BUSINESS WIRE)–
AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an approved test.

The approval was granted under the US Food and Drug Administration’s (FDA) Real-Time Oncology Review (RTOR) pilot program. Five other countries participated in a concurrent submission and review process through FDA’s Project Orbis.

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and nearly half of patients diagnosed in Stage IB, and over three quarters of patients diagnosed in Stage IIIA, experience recurrence within five years.1-4

The approval was based on results from the ADAURA Phase III trial where TAGRISSO demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the primary analysis population of patients with Stage II and IIIA EGFRm NSCLC, and also in the overall trial population of patients with Stage IB-IIIA disease, a key secondary endpoint.

Roy S. Herbst, MD, PhD, chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT and principal investigator in the ADAURA Phase III trial, said: “Adjuvant TAGRISSO has demonstrated an unprecedented disease-free survival benefit for early-stage lung cancer patients with EGFR mutations who face high rates of recurrence even after successful surgery and subsequent chemotherapy. This approval reinforces how critical it is to test all lung cancer patients for EGFR mutations before deciding how to treat them and regardless of their stage at diagnosis. This will help ensure as many patients as possible can benefit from this potentially practice-changing treatment.”

Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: “For the first time, a targeted, biomarker-driven treatment option is available to patients in the US with early-stage EGFR-mutated lung cancer. This approval dispels the notion that treatment is over after surgery and chemotherapy, as the ADAURA results show that TAGRISSO can dramatically change the course of this disease. We remain committed to treating cancer patients earlier, when they may still have a chance of being cured.”

Adjuvant treatment with TAGRISSO reduced the risk of disease recurrence or death by 83% in the primary endpoint of DFS in patients with Stage II and IIIA disease (hazard ratio [HR] 0.17; 95% confidence interval [CI] 0.12-0.23; p<0.0001). DFS results in the overall trial population of patients with Stage IB-IIIA disease showed TAGRISSO reduced the risk of disease recurrence or death by 80% (HR 0.20; 95% CI 0.15-0.27; p<0.0001). At two years, 89% of patients treated with TAGRISSO remained alive and disease free versus 52% on placebo after surgery, the current standard of care. The safety and tolerability of TAGRISSO in this trial was consistent with previous trials in the metastatic setting.

TAGRISSO was recently granted Breakthrough Therapy Designation for patients in the early-stage disease setting by the US FDA. In April 2020, an Independent Data Monitoring Committee recommended for the ADAURA trial to be unblinded two years early based on a determination of overwhelming efficacy. Investigators and patients continue to participate in the trial and remain blinded to treatment. The results from the ADAURA trial were presented during the plenary session of the American Society of Clinical Oncology ASCO20 Virtual Scientific Program in May 2020 and were recently published in The New England Journal of Medicine.

The US regulatory submission was reviewed under the FDA’s RTOR pilot program which aims to ensure that safe and effective treatments are available to patients as early as possible. Five national health authorities collaborated with the FDA on this review through Project Orbis, an initiative of the FDA Oncology Center of Excellence, which provides a framework for concurrent submission and review of oncology medicines among international partners. These included Health Canada, the Australian Therapeutic Goods Administration, the Brazilian Health Regulatory Agency (Anvisa), Swissmedic, and Singapore Health Sciences Authority. The UK Medicines and Healthcare products Regulatory Agency participated in the review as an observer.

In China, TAGRISSO is under priority review for the adjuvant treatment of patients with early-stage EGFRm NSCLC based on the ADAURA Phase III trial. This indication is also under regulatory review in the EU and additional global submission discussions are ongoing.

TAGRISSO is a once-daily oral tablet approved for the 1st-line treatment of patients with metastatic EGFRm NSCLC and for the treatment of metastatic EGFR T790M mutation-positive NSCLC in the US, Japan, China, the EU and many other countries around the world.

TAGRISSO Important Safety Information

  • There are no contraindications for TAGRISSO
  • Interstitial lung disease (ILD)/pneumonitis occurred in 3.7% of the 1479 TAGRISSO-treated patients; 0.3% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
  • Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1479 TAGRISSO-treated patients in clinical trials, 0.8% were found to have a QTc >500 msec, and 3.1% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
  • Cardiomyopathy occurred in 3% of the 1479 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.2% of 1233 patients who had baseline and at least one follow-up LVEF assessment. In the ADAURA study, 1.5% (5/325) of TAGRISSO-treated patients experienced LVEF decreases ≥10% from baseline and a drop to <50%. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
  • Keratitis was reported in 0.7% of 1479 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
  • Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
  • Postmarketing cases of cutaneous vasculitis including leukocytoclastic vasculitis, urticarial vasculitis, and IgA vasculitis have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if cutaneous vasculitis is suspected, evaluate for systemic involvement, and consider dermatology consultation. If no other etiology can be identified, consider permanent discontinuation of TAGRISSO based on severity
  • Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
  • Most common (≥20%) adverse reactions, including laboratory abnormalities, were leukopenia, lymphopenia, thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, neutropenia, dry skin, stomatitis, fatigue, and cough

INDICATIONS

  • TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
  • TAGRISSO is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
  • TAGRISSO is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy

For additional information, please see the complete Prescribing Information, including Patient Information.

Lung cancer

Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths.5 Lung cancer is broadly split into NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.6 The majority of all NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis.1-3

For those with resectable tumors, the majority of patients eventually develop recurrence despite complete tumor resection and adjuvant chemotherapy.4 Early-stage lung cancer diagnoses are often only made when the cancer is found on imaging for an unrelated condition.7,8

Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.9-11 These patients are particularly sensitive to treatment with EGFR-tyrosine kinase inhibitors (TKIs) which block the cell-signaling pathways that drive the growth of tumor cells.12

About ADAURA

ADAURA is a randomized, double-blinded, global, placebo-controlled Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II, IIIA EGFRm NSCLC following complete tumor resection and adjuvant chemotherapy as indicated. Patients were treated with TAGRISSO 80 mg once-daily oral tablets or placebo for three years or until disease recurrence.

The trial enrolled in more than 200 centers across more than 20 countries, including the US, in Europe, South America, Asia and the Middle East. The primary endpoint was DFS in Stage II and IIIA patients and a key secondary endpoint was DFS in Stage IB, II and IIIA patients. The data readout was originally anticipated in 2022. The trial will continue to assess overall survival.

About TAGRISSO

TAGRISSO® (osimertinib) is a third-generation, irreversible EGFR-TKI with clinical activity against central nervous system metastases. TAGRISSO 40 mg and 80 mg once-daily oral tablets have received approval in the US, Japan, China, the EU and many countries around the world for 1st-line EGFRm metastatic NSCLC and EGFR T790M mutation-positive metastatic NSCLC.

AstraZeneca in lung cancer

AstraZeneca has a comprehensive portfolio of approved and potential new medicines in late-stage development for the treatment of different forms of lung cancer spanning different histologies, several stages of disease, lines of therapy and modes of action.

AstraZeneca aims to address the unmet needs of patients with EGFRm tumors as a genetic driver of disease with the approved medicinesgefitinib and TAGRISSO, and its ongoing LAURA, NeoADAURA, and FLAURA2 Phase III trials.

AstraZeneca is committed to addressing tumor mechanisms of resistance through the ongoing Phase II trials SAVANNAH and ORCHARD which test TAGRISSO in combination with savolitinib, a selective inhibitor of c-MET receptor tyrosine kinase, along with other potential new medicines.

AstraZeneca in oncology

AstraZeneca has a deep-rooted heritage in oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers.

By harnessing the power of six scientific platforms – Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, Antibody Drug Conjugates, Epigenetics, and Cell Therapies – and by championing the development of personalized combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit https://www.astrazeneca-us.com/ and follow us on Twitter @AstraZenecaUS.

References

  1. Cagle P, et al. Lung Cancer Biomarkers: Present Status and Future Developments. Arch Pathol Lab Med. 2013;137:1191-1198.
  2. Le Chevalier T. Adjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer: Where is it Going? Ann Oncol. 2010;21:196-198.
  3. Datta D, et al. Preoperative Evaluation of Patients Undergoing Lung Resection Surgery. Chest. 2003;123:2096-2103.
  4. Pignon et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
  5. World Health Organization. International Agency for Research on Cancer. Lung Fact Sheet. http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed August 2020.
  6. LUNGevity Foundation. Types of Lung Cancer. https://www.lungevity.org/about-lung-cancer/lung-cancer-101/types-of-lung-cancer. Accessed August 2020.
  7. Sethi S, et al. Incidental Nodule Management – Should There Be a Formal Process? J Thorac Dis. 2016;8:S494-S497.
  8. LUNGevity Foundation. Screening and Early Detection. https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection#1. Accessed August 2020.
  9. Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013;6:2800-2812.
  10. Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29:2121-2127.
  11. Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013:66:79-89.
  12. Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061.

US-43163 Last Updated 12/20

Media Inquiries

Michele Meixell +1 302 885 2677

Brendan McEvoy +1 302 885 2677

KEYWORDS: Singapore Australia Brazil Switzerland Australia/Oceania United States South America United Kingdom North America Asia Pacific Europe China Japan Canada Delaware

INDUSTRY KEYWORDS: Other Health Research General Health Pharmaceutical Oncology Clinical Trials Science Surgery Cardiology FDA Other Science Health

MEDIA:

Logo
Logo

Strong Housing Market Fundamentals to Remain a Constant in 2021, According to First American Potential Home Sales Model

Strong Housing Market Fundamentals to Remain a Constant in 2021, According to First American Potential Home Sales Model

—Strong underlying fundamentals shaped the housing market’s remarkable 2020 comeback story and, with a vaccine rollout underway, the stage is set for another strong year in 2021, says Chief Economist Mark Fleming—

SANTA ANA, Calif.–(BUSINESS WIRE)–First American Financial Corporation (NYSE: FAF), a leading global provider of title insurance, settlement services and risk solutions for real estate transactions, today released First American’s proprietary Potential Home Sales Model for the month of November 2020.

November 2020 Potential Home Sales

  • Potential existing-home sales increased to a 6.05 million seasonally adjusted annualized rate (SAAR), a 3.0 percent month-over-month increase.
  • This represents a 73.5 percent increase from the market potential low point reached in February 1993.
  • The market potential for existing-home sales increased 10.0 percent compared with a year ago, a gain of nearly 551,135 (SAAR) sales.
  • Currently, potential existing-home sales is 743,100 million (SAAR), or 10.9 percent below the pre-recession peak of market potential, which occurred in April 2006.

Market Performance Gap

  • The market for existing-home sales outperformed its potential by 1.4 percent or an estimated 84,262 (SAAR) sales.
  • The market performance gap increased by an estimated 16,847 (SAAR) sales between October 2020 and November 2020.

Chief Economist Analysis: Housing Market Potential Up 10 Percent Year Over Year

“The housing market continues to impress, even as it enters the colder months, which is traditionally real estate’s slow season. After falling to a near-decade low in May due to pandemic-driven pressures, existing-home sales hit a 14-year high in October,” said Mark Fleming, chief economist at First American. “In November, our measure of the market potential for existing-home sales increased 10 percent, compared with one year ago, to a 6.05 million seasonally adjusted annualized rate (SAAR) of sales. While the housing market rebound has been nothing short of incredible, the forces driving the rebound existed prior to the pandemic. Looking ahead, the good news for housing market potential is these fundamental forces are likely to remain constant throughout 2021.”

The Housing Markets Constants

  • Rising House-Buying Power: “How much home one can afford to buy given their income and the prevailing mortgage rate is a primary driver of home-buying demand. Compared with one year ago, falling mortgage rates and rising incomes for those still employed resulted in nearly more 352,000 potential home sales,” said Fleming. “Consensus forecasts estimate the 30-year, fixed mortgage rate will likely average 3 percent next year, with forecasts ranging from 2.8 percent to 3.3 percent, so house-buying power is expected to remain strong in 2021 and continue to drive demand for homes.”
  • Millennial Demand: “Household formation contributed to a gain of approximately 161,000 potential home sales in November relative to one year ago. The homeownership rate has been steadily rising since 2016, mostly due to millennial household formation,” said Fleming. “The bulk of millennials turned 30 this year and are beginning to age into their prime home-buying years, a demographic tailwind that will continue to boost housing market potential for years to come.”
  • Limited Supply of Homes for Sale: “New- and existing-home inventory sits at historical lows. Tenure length, the average length of time someone lives in their home, continues to rise, reaching a historically high level of 10.5 years in November. The increase in tenure length reduced the potential for existing-home sales by nearly 175,000 in November,” said Fleming. “Rising tenure length means fewer and fewer people are listing their homes for sale, keeping housing supply tight. Additionally, the lack of new construction in November contributed to a loss of approximately 1,600 potential home sales relative to one year ago. While builders are working hard to deliver more supply to meet rising demand, it will take years to make up the decade-long gap. Fewer existing homeowners listing their homes for sale and a new-home construction deficit means the limited supply of homes for sale will remain another 2021 constant.”
  • Rapid House Price Appreciation: “Strong demand from home buyers armed with robust buying power combined with limited supply results in heightened competition and bids up prices, a dynamic that defined the housing market in 2020. Faster house price appreciation resulted in a gain of approximately 160,000 potential home sales in November due to rising equity levels,” said Fleming. “As homeowners gain equity in their homes, they are more tempted to consider using the equity to purchase a larger or more attractive home. The allure of the more attractive house can help encourage more homeowners to list their homes for sale. This partially explains why home sales in the highest price tiers experienced the greatest year-over-year growth in October. Since the supply and demand dynamics will continue in 2021, we expect to see continued house price appreciation.”

The Question Mark

  • Credit Conditions: “When lending standards are tight, fewer people can qualify for a mortgage, resulting in less first-time home buyer demand and increasing the likelihood that some homeowners stay in their current homes because they are ineligible for a new mortgage. When the pandemic hit, lenders tightened their lending criteria to protect against the potential for increased delinquencies. At the height of the pandemic-driven housing market contraction in April, tight credit conditions reduced the potential for existing-home sales by over 900,000 sales relative to a year ago,” said Fleming. “As the uncertainty has subsided, credit conditions have loosened. In November, looser credit conditions increased potential home sales by 54,000 relative to one year ago. What lending standards will look like in 2021 remains unclear and will depend on economic conditions in the coming months.”

The Housing Market’s 2020 Tailwinds Will Carry Through to 2021

“The potential for a successful vaccine rollout in the first half of 2021 bodes well for the economic recovery in the second half of 2021. But, first, we need to get through the winter, luckily a time when the housing market is usually slow. The good news is that housing market constants – low rates, limited supply and demographic demand – are exactly that, constants,” said Fleming. “Strong underlying fundamentals shaped the housing market’s remarkable comeback story in 2020, helping overcome the pandemic-driven spring slowdown and ultimately fueling a record-breaking year. Add a vaccine to the story, and the stage is set for another strong year in 2021.”

Next Release

The next Potential Home Sales Model will be released on January 21, 2021 with December 2020 data.

About the Potential Home Sales Model

Potential home sales measures existing-homes sales, which include single-family homes, townhomes, condominiums and co-ops on a seasonally adjusted annualized rate based on the historical relationship between existing-home sales and U.S. population demographic data, homeowner tenure, house-buying power in the U.S. economy, price trends in the U.S. housing market, and conditions in the financial market. When the actual level of existing-home sales are significantly above potential home sales, the pace of turnover is not supported by market fundamentals and there is an increased likelihood of a market correction. Conversely, seasonally adjusted, annualized rates of actual existing-home sales below the level of potential existing-home sales indicate market turnover is underperforming the rate fundamentally supported by the current conditions. Actual seasonally adjusted annualized existing-home sales may exceed or fall short of the potential rate of sales for a variety of reasons, including non-traditional market conditions, policy constraints and market participant behavior. Recent potential home sale estimates are subject to revision to reflect the most up-to-date information available on the economy, housing market and financial conditions. The Potential Home Sales model is published prior to the National Association of Realtors’ Existing-Home Sales report each month.

Disclaimer

Opinions, estimates, forecasts and other views contained in this page are those of First American’s Chief Economist, do not necessarily represent the views of First American or its management, should not be construed as indicating First American’s business prospects or expected results, and are subject to change without notice. Although the First American Economics team attempts to provide reliable, useful information, it does not guarantee that the information is accurate, current or suitable for any particular purpose. © 2020 by First American. Information from this page may be used with proper attribution.

About First American

First American Financial Corporation (NYSE: FAF) is a leading provider of title insurance, settlement services and risk solutions for real estate transactions that traces its heritage back to 1889. First American also provides title plant management services; title and other real property records and images; valuation products and services; home warranty products; property and casualty insurance; banking, trust and wealth management services; and other related products and services. With total revenue of $6.2 billion in 2019, the company offers its products and services directly and through its agents throughout the United States and abroad. In 2020, First American was named to the Fortune 100 Best Companies to Work For® list for the fifth consecutive year. More information about the company can be found at www.firstam.com.

 

Media Contact:

Marcus Ginnaty

Corporate Communications

First American Financial Corporation

(714) 250-3298

Investor Contact:

Craig Barberio

Investor Relations

First American Financial Corporation

(714) 250-5214

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Residential Building & Real Estate Insurance Construction & Property Banking

MEDIA:

Logo
Logo

Velodyne Joins the Qualcomm Smart Cities Accelerator Program

Velodyne Joins the Qualcomm Smart Cities Accelerator Program

Velodyne Lidar Advances Smart City Industry

SAN JOSE, Calif.–(BUSINESS WIRE)–Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced it has joined the Qualcomm® Smart Cities Accelerator Program to promote using lidar technology in smart city solutions. By becoming part of the Qualcomm Smart Cities ecosystem, Velodyne will work more closely with Qualcomm Technologies, Inc., governments and solution developers to create smart city applications that improve public services and enhance safety and quality of life.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005093/en/

Smart city solutions can use Velodyne’s lidar sensors to measure and monitor conditions in areas such as vehicle traffic, pedestrian safety, parking space management, speed measurement, V2X communications, queue and asset management, security and more. (Photo: Velodyne Lidar, Inc.)

Smart city solutions can use Velodyne’s lidar sensors to measure and monitor conditions in areas such as vehicle traffic, pedestrian safety, parking space management, speed measurement, V2X communications, queue and asset management, security and more. (Photo: Velodyne Lidar, Inc.)

Smart city solutions can use Velodyne’s lidar sensors to measure and monitor conditions in areas such as pedestrian safety, vehicle traffic, parking space management, speed measurement, V2X communications, queue and asset management, security and more. The sensors can collect highly accurate, detailed 3D information about people, vehicles, bicyclists, public spaces and more, while preserving anonymity.

“We are pleased to welcome Velodyne Lidar to the Qualcomm Smart Cities Accelerator Program to implement cutting-edge lidar solutions for a transparent understanding of the smart environment,” said Ashok Tipirneni, Director, Qualcomm Technologies, Inc. and Head of Platform Product Management for Smart Cities. “Velodyne’s lidar sensors and comprehensive 3D data can help equip our Smart Campus and smart city ecosystem members with enhanced safety measures and streamlined operations.”

Until recently, existing camera-based ITS traffic monitoring technologies have been widely used to study traffic flow rates, occupancy, average speed and spot speed. However, as alternative sensors come onto the market, the weaknesses of camera-based approaches become more apparent. For example, cameras have been shown to suffer in low-light conditions, are prone to optical illusions and do not allow for people’s privacy. Velodyne’s lidar sensors provide robust 3D data that allows for superior object detection and tracking in a wide variety of lighting and weather conditions. Furthermore, Velodyne’s sensors do not recognize people’s characteristics, such as their faces or the color of their skin, making it an ideal sensor to support the needs of municipalities without compromising their citizens’ privacy. With Velodyne lidar, smart city applications can advance safety, social welfare and operational efficiency.

As a real-time application demonstration of the significant value that Velodyne’s lidar can bring to smart city applications, Velodyne and Qualcomm Technologies plan to deploy a Velodyne sensor on the Qualcomm Smart Campus. The lidar is intended to be placed indoors to track people as they move around in a public space. The data can help Qualcomm Technologies to detect traffic and usage patterns so the company can better understand utilization rates and make adjustments to facilities. Velodyne worked with Infinite Computer Solutions and Seoul Robotics, an Automated with Velodyne partner, to build the application.

“The combination of Velodyne’s lidar and Qualcomm Technologies edge computing and 5G capabilities creates a powerful asset for developers to make their smart city ideas a potent solution,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Participating in the Qualcomm Smart Cities Accelerator Program will help us connect with governments and solution providers to build lidar-based smart city applications that transform city infrastructure and services.”

Velodyne’s sensors provide rich computer perception data that make it quick and easy for developers, cities, municipalities, government agencies and enterprises to build highly accurate 3D models of any environment. The sensors deliver a high-resolution image that can accurately measure and analyze the environment. Their durability, reliability, power-efficiency and versatility make them ideal solutions for demanding smart city applications.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “plans,” “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “intends,” “believes,” “seeks,” “can,” “may,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; uncertainties related to Velodyne’s estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.

Qualcomm Smart Cities Accelerator Program is a program of Qualcomm Technologies, Inc. and/or its subsidiaries.

Investor Relations

Andrew Hamer

Chief Financial Officer

[email protected]

Media

Landis Communications Inc.

Sean Dowdall

(415) 286-7121

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Automotive Technology Performance & Special Interest Audio/Video Construction & Property Urban Planning

MEDIA:

Photo
Photo
Smart city solutions can use Velodyne’s lidar sensors to measure and monitor conditions in areas such as vehicle traffic, pedestrian safety, parking space management, speed measurement, V2X communications, queue and asset management, security and more. (Photo: Velodyne Lidar, Inc.)
Photo
Photo
Velodyne Lidar’s Ultra Puck™ sensors can collect highly accurate, detailed 3D information in smart city applications that improve public services and enhance safety and quality of life. (Photo: Velodyne Lidar, Inc.)
Logo
Logo

J2 Global to Participate in Two Investor Conferences in January

J2 Global to Participate in Two Investor Conferences in January

LOS ANGELES–(BUSINESS WIRE)–
J2 Global, Inc. (NASDAQ:JCOM), a leading Internet information and services company, today announced its participation in two investor conferences in January.

Details of the conferences are as follows:

Citi Global TMT West Virtual Conference

Location: Virtual

Date and time: January 5, 2021, 2:00pm (ET)

Webcast: https://kvgo.com/citi/j2-global-january-2021

Needham Annual Growth Conference

Location: Virtual

Date and time: January 12, 2021, 3:30pm (ET)

Webcast: https://wsw.com/webcast/needham103/jcom/2235126

About J2 Global

J2 Global, Inc. (NASDAQ: JCOM) is a leading internet information and services company consisting of a portfolio of brands including IGN, Mashable, Humble Bundle, Speedtest, PCMag, RetailMeNot, Offers.com, Spiceworks, Everyday Health, BabyCenter and What To Expect in its Digital Media business and eFax, eVoice, iContact, Campaigner, Vipre, IPVanish and KeepItSafe in its Cloud Services business. J2 reaches more than 230 million people per month across its brands. As of December 31, 2019, J2 had achieved 24 consecutive fiscal years of revenue growth. For more information about J2, please visit http://www.j2global.com.

Scott Turicchi

(800) 577-1790

J2 Global, Inc.

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Internet Data Management

MEDIA:

Logo
Logo

Evoqua Acquires Ultrapure’s Industrial Water Business in Houston and Dallas

Evoqua Acquires Ultrapure’s Industrial Water Business in Houston and Dallas

PITTSBURGH & DALLAS–(BUSINESS WIRE)–
Evoqua Water Technologies (NYSE: AQUA), an industry leader in mission-critical water treatment solutions, today announced it has acquired the industrial water business of privately-held Ultrapure & Industrial Services, LLC, a subsidiary of Driessen Water, Inc. Ultrapure’s industrial operations are based out of Houston and Dallas, Texas. This acquisition will further strengthen Evoqua’s service capabilities in the Houston and Dallas markets and the surrounding regions. Terms of the deal were not disclosed.

Ultrapure’s Texas-based operations focus on water purification services and equipment, serving the healthcare, laboratory, power, microelectronics, food and beverage, oil and gas, commercial, and manufacturing markets. Ultrapure provides its customers with a variety of water treatment products and services, including service deionization, reverse osmosis, UV, and ozonation.

“For over 20 years, Ultrapure’s industrial operations has built a reputation as a trusted partner, providing reliable water solutions and services to their broad customer portfolio,” said Evoqua Chief Executive Officer Ron Keating. “We are delighted to welcome the Houston and Dallas Ultrapure team to the Evoqua family.”

For more information, visit https://www.evoqua.com.

About Evoqua Water Technologies

Evoqua Water Technologies is a leading provider of mission-critical water and wastewater treatment solutions, offering a broad portfolio of products, services, and expertise to support industrial, municipal, and recreational customers who value water. Evoqua has worked to protect water, the environment, and its employees for more than 100 years, earning a reputation for quality, safety, and reliability around the world. Headquartered in Pittsburgh, Pennsylvania, the company operates in more than 160 locations across ten countries. Serving more than 38,000 customers and 200,000 installations worldwide, our employees are united by a common purpose: Transforming Water. Enriching Life.

Evoqua Water Technologies Corp.

Media

Sarah Brown, 506-454-5495 (office)

[email protected]

Investors

Dan Brailer, 724-720-1605 (office)

412-977-2605 (mobile)

[email protected]

KEYWORDS: Texas Pennsylvania United States North America

INDUSTRY KEYWORDS: Energy Environment Utilities

MEDIA:

New Look Vision Group Inc. Completes Acquisition of The Vision Clinic

MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) — New Look Vision Group Inc. (TSX: BCI) (“New Look Vision Group”), announced today that it has completed its acquisition of a majority position in The Vision Clinic (“TVC”). Founded in 1994 by the Nekoui family and based in Grimsby, Ontario, the business is a leading local player in Southern Ontario. TVC operates 12 retail optical clinics under The Vision Clinic banner stretching from Hamilton eastwards through to the Niagara Peninsula. The family who founded the business will remain on as minority shareholders. The purchase price for the majority position is $18.8 million, subject to customary price adjustments and was financed by New Look Vision Group with cash on hand.

Antoine Amiel, President and CEO of New Look Vision Group stated that: “We feel very privileged to welcome The Vision Clinic team into our organization and look forward to partnering with the founders. The transaction will be a major step forward for both organizations. The Vision Clinic, based in Grimsby, Ontario serves one of the fastest growing regions of Canada’s most populous province and will operate as a stand-alone business unit within New Look Vision Group. The Vision Clinic adds to New Look Vision Group’s current network in Ontario a strong platform for the consolidation of the optician based retail segment of the Canadian optical industry. This transaction reinforces New Look Vision Group’s position as the largest Canadian retail optical company with a network in excess of 400 stores.”

Foad Nekoui, one of the founders of TVC stated that: “Since 1994 we have been faithfully serving our patients and providing them with the vision care they have come to know and expect from The Vision Clinic. A partnership with New Look Vision Group will ensure the continuity of this long standing commitment. The motivation to retain a minority ownership position is driven by the advantages we see of partnering with a company who is committed to the advancement of vision health not only in Southern Ontario, but across the country for all Canadians.”

As of November 30, 2020, New Look Vision Group had 15,660,199 Class A common shares issued and outstanding. New Look Vision Group is a leader in the eye care industry in Canada and recently entered the United States. New Look Vision Group has a network of 405 locations operating mainly under the Iris, New Look Eyewear, Vogue Optical, Greiche & Scaff and Edward Beiner banners and a laboratory facility using state-of-the-art technologies. Tax information regarding payments to shareholders is available at www.newlookvision.ca in the Investors section.

All statements other than statements of historical fact contained in this press release are forward-looking statements, including, without limitation, statements regarding the future financial position, business strategy, projected costs and plans and objectives of, or involving New Look Vision Group. Readers can identify many of these statements by looking for words such as “believe”, “expects”, “will”, “intends”, “projects”, “anticipates”, “estimates”, “plans”, “may”, “would” or similar words or the negative thereof. There can be no assurance that the plans, intentions or expectations upon which these forward-looking statements are based will be achieved. Forward-looking statements are subject to risks, uncertainties and assumptions. Although management of New Look Vision Group believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. Some of the factors which could affect future results and could cause results to differ materially from those expressed in the forward-looking statements contained herein include: pending and proposed legislative or regulatory developments, competition from established competitors and new market entrants, technological change, interest rate fluctuations, general economic conditions, acceptance and demand for new products and services, and fluctuations in operating results, as well as other risks included in New Look Vision Group’s current Annual Information Form (AIF) which can be found at www.sedar.com. The forward-looking statements included in this press release are made as of the date hereof, and New Look Vision Group undertakes no obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, except as provided by law.

For additional information please see our Web site www.newlookvision.ca. For enquiries, please contact Lise Melanson (514) 877-4119. 



New Survey Reveals That Two-Thirds of People are Concerned with Grease and Wine Stains this Holiday Season and This Year 60% of People are Filling Their Carts With Cleaning Supplies

Tide, America’s #1 Laundry Detergent, Offers Tips For Tackling Top Holiday Stains and Introduces New Tide Hygienic Clean Heavy Duty 10X

CINCINNATI, Dec. 21, 2020 (GLOBE NEWSWIRE) — While Americans may be scaling down holiday celebrations this year, they still want to look their best! A new survey conducted by Toluna and commissioned by Tide shows about two-thirds of Americans are concerned about stains this holiday season. With more breaking out pots and pans for small household gatherings, kitchen stains like oil and grease surged as the top concern over condiments and beverages. Over 40% of Americans foresee grease and oil as the biggest challenge in preparation for their holiday meal. Wine ranks second, with more than 20% noting the beverage as a top concern. With food and wine stains top of mind, it’s no surprise that Americans are making necessary preparations. In fact, nearly 60% say that household cleaning products, such as laundry detergent, will take up more room in their shopping cart this year.

When it comes to laundry, a new option on shelves is from Tide, America’s #1 laundry detergent: Tide Hygienic Clean Heavy Duty 10X. Powered with deeper cleaning technology, Tide’s newest product is designed to remove both visible and invisible dirt from fabrics down to the microscopic level.

“The dirt residue and the body soils left on your garments aren’t necessarily visible and just because you can’t see it, doesn’t mean it isn’t there. In fact, as little as 30% of the soils in your laundry are visible, things like food, dirt and grass stains, while as much as 70% of laundry soils can be made up of invisible dirty such as body oils,” said Jennifer Ahoni, NA Fabric Care Senior Scientific Communications Manager. Tide Hygienic Clean Heavy Duty 10X is not only the #1 Stain and Odor Fighter detergent*, but its innovative technology is formulated with 50% more cleaning power**.

For more than 70 years, Tide has set the highest standards for laundry care. Below are some tips from Tide to help clean the top two stain makers Americans are concerned about, along with some other common holiday stains, whether it be on your table linens or favorite blouse:

  • Grease or Oil — Rinse the stain immediately with cold water. Gently rub dish soap into the stain to loosen it, then rinse with water. Repeat if necessary. Pretreat the stain by applying Tide Hygienic Clean Heavy Duty 10X, rubbing the fabric together gently or with a soft-bristled toothbrush to work the detergent into the fibers. Let stand for five minutes. Without rinsing off the detergent, place soiled laundry into the washer with other items and wash on the usual cycle, on warm.
  • Wine — Pour Tide Hygienic Clean Heavy Duty 10X detergent onto the stain, and either rub the fabric together gently or use a soft-bristled toothbrush to work it into the fibers. Let stand for five minutes before rinsing with cold water.
  • Lipstick — Best removed by pretreating the fabric by pouring Tide Hygienic Clean Heavy Duty 10X detergent on the stain, covering it completely. Use a soft-bristled toothbrush to spread the detergent into the fibers or rub the fabric together gently. Let it sit for five minutes.
  • Coffee — Run cold water over the stain, then pour Tide Hygienic Clean Heavy Duty 10X detergent onto it. Rub the fabric together gently or use a soft-bristled toothbrush to work the detergent into the fibers and let the stain sit for a few minutes.
  • Gravy — Pour Tide Hygienic Clean Heavy Duty 10X directly onto the gravy stain, completely covering it. Rub the fabric together gently or use a soft-bristled toothbrush to work the detergent into the fabric and let it sit for five minutes.

Tide encourages everyone to follow the Centers for Disease Control and Prevention Guidelines for celebrating the holidays when it comes to size of gatherings and how to best prepare.

Visit www.tide.com for more information.

*among liquid laundry detergents and liquid laundry detergent pacs, respectively
**vs. Tide Original Liquid
______________________________________________________________________________

About Tide

For over 70 years Tide has been changing the way we do laundry and continually helping deliver the cleanest clothes you can get. To meet consumers’ diverse laundry needs, Tide offers its cleaning in a variety of products including Tide Hygienic Clean Heavy Duty 10X, Tide Free & Gentle, Tide Plus Downy, Tide Sport Odor Defense, Tide Plus Ultra OXI, Tide Plant Based, Tide Simply and Studio by Tide. For consumers’ on-the-go stain removal needs, Tide to Go Pens and Wipes help remove fresh food and drink stains on the spot. Visit www.tide.com for helpful product information and practical tips on laundry care.

                                                                                                     
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.

About P&G’s COVID-19 Contributions

P&G is stepping up to provide much needed product donations and financial support in response to the global COVID-19 crisis. Our contributions of product and in-kind support now exceed $15 million and will continue to increase as we work with communities around the world to understand how we can best serve them. Millions of P&G products are being donated from 30 brands in more than 20 countries, with more on the way. These donations ensure that families who do not have basic access to the everyday essentials many of us take for granted, can have the cleaning, health and hygiene benefits P&G brands can provide. Our contributions are broad-based with cash support to ensure disaster relief organizations can meet immediate needs, including hygiene education and medical equipment and supplies. We’re partnering with some of the world’s leading relief organizations, including the International Federation of the Red Cross, Americares and Direct Relief, and key regional organizations such as Feeding America, Matthew 25: Ministries, the China Youth Development Foundation, One Foundation, the Korea Disaster Relief Association, the United Way, and more.

Contact

Rotha Brauntz
[email protected]

Or

Patricia Jones
[email protected]

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/81f02a7d-2fc0-40c4-b1c5-c69e2f5416c1

https://www.globenewswire.com/NewsRoom/AttachmentNg/28dcee4e-207a-4899-957c-4b6ea8f2ca53



Blackwells Offers to Acquire Monmouth Real Estate Investment Corporation


Makes All-Cash Offer to Acquire Company for $18.00 per Share


Offer Represents 21.6% Premium to Unaffected Share Price as of December 1, 2020,



and 24.8% Premium Over 6-Month VWAP


Calls on Board to Form Independent Special Committee to Evaluate Offer

NEW YORK, Dec. 21, 2020 (GLOBE NEWSWIRE) —  Blackwells Capital LLC (together with its affiliates “Blackwells”), an alternative investment management firm that is one of the largest owners of Monmouth Real Estate Investment Corporation (NYSE: MNR) (“Monmouth” or the “Company”), announced today that on December 18, 2020, it submitted an offer letter to the Company’s Board of Directors (the “Board”) outlining an all-cash offer to acquire Monmouth for $18.00 per share.

Blackwells’ offer represents a 21.6% premium to the unaffected share price as of December 1, 2020 (at which time Blackwells privately submitted its first all-cash offer to the Chairman of the Board, Eugene Landy), and exceeds the unaffected three-month and six-month VWAPs by 23.8% and 24.8%, respectively. The all-cash transaction is valued at approximately $3.8 billion, including the assumption of debt.

Jason Aintabi, Chief Investment Officer of Blackwells, said, “As a public company, Monmouth has significantly underperformed comparable industrial REITs over the last five years, further exacerbated by the stock’s lack of liquidity. Blackwells’ cash offer provides shareholders immediate liquidity at a 17% premium above consensus net asset value – though the stock has long traded at a discount to it. Our offer also represents a premium to unaffected price well above the average premium for completed REIT deals over the last five years.”  

Added Aintabi, “After we privately made our first offer on December 1, I had a constructive dialog with the Company’s CEO Michael Landy, who expressed enthusiasm and a desire to engage. Soon thereafter, we received a puzzling follow-up letter from Michael’s father, Chairman Eugene Landy, indicating that on second thought Monmouth would not engage with us, because exploring our offer would ‘not be in the best interests of the company.’ For myriad and tangible reasons, Monmouth in its current state, does not belong in the public markets. Pursuing our offer is the best way to maximize value for all Monmouth shareholders.”

Blackwells believes that a Special Committee of the Board, excluding Landy family members, Landy family affiliates, and those directors affiliated with UMH Properties, Inc., should be formed to objectively review the new Blackwells offer.

Blackwells is now making its offer public, to ensure all Monmouth shareholders have equal access to this information, in light of unusual trading volumes and share price dynamics since the submission of our first offer privately to the Company.

The full text of the offer letter follows:

December 18, 2020

Mr. Eugene W. Landy
Chairman of the Board and Executive Director
Monmouth Real Estate Investment Corp.
401 Crawfords Corner
Suite 1405
Holmdel, NJ 07733

RE: Proposal for Acquisition of Monmouth

Dear Mr. Landy:

It is my pleasure on behalf of Blackwells Capital LLC (“Blackwells” or “we”) to submit this preliminary proposal for the negotiated acquisition of Monmouth Real Estate Investment Corporation (the “Company” or “you”) by Blackwells (the “Transaction”). Blackwells has made a substantial investment in the common stock of the Company and is one of the Company’s largest shareholders.

Blackwells proposes to acquire 100% of the outstanding equity interests in the Company for $18.00 per share of common stock, par value $0.01 per share, in cash, subject to the terms set forth below (the “Proposal”). The Transaction will provide your stockholders with a substantial premium to recent trading prices of the stock and an attractive value for their shares. Our Proposal provides stockholders with compelling value, low execution risk and a quick timeline to closing.

Blackwells is a leading global alternative asset manager, founded in 2016 by Jason Aintabi, its Chief Investment Officer. Blackwells has an extensive background in real estate, with existing public and private investments in similar assets to the Company. Throughout their careers, Blackwells’ principals have invested globally on behalf of leading public and private equity firms and have held operating roles and served on the boards of media, energy, technology, insurance and real estate enterprises.

Blackwells looks forward to working collaboratively with the Company’s Board of Directors to finalize our Proposal. Having analyzed publicly available information about the Company comprehensively, we believe you have an attractive portfolio of high-quality properties, demonstrated portfolio and NOI growth, and conservative expense management. We have a tremendous amount of respect for the Company’s history, and the amount of diligent effort and foresight the Landy family has employed in achieving the Company’s success to date.


Proposal


Value

: Blackwells proposes an all-cash acquisition of 100% of the outstanding shares of the Company for $18.00 per share of common stock, par value $0.01 per share, reflecting a 21.6% premium to the unaffected market price of $14.80 prior to our offer and premiums to the then 52-week high ($15.53) and 52-week low ($8.42) of 15.9% and 113.8%, respectively. Notably, the proposed price exceeds the unaffected 1-month, 3-month, and 6-month VWAPs by 19.3%, 23.8%, and 24.8%, respectively1.


Financing
: We would expect to finance the Transaction with a combination of debt and equity. Blackwells’ internal resources, as well as certain limited partner commitments, conditioned on completion of satisfactory diligence investigations, will fund the equity portion of the Transaction. We have engaged [REDACTED] to arrange the debt financing of the Proposal; its highly confident letter is attached as Appendix I to this letter.

Below please find our expected sources and uses to finance the Transaction:

($ in millions)                                                  Sources & Uses

2
       
Uses of Funds $ %
Purchase of Equity          [REDACTED] [REDACTED]
Committed Acquisitions             
Refinanced Debt            
Refinanced Preferred             
Mortgage Defeasance Costs             
Debt Financing Expenses             
Management Change of Control             
Advisory Expenses            
Total         $
3,780
100.0%  

Sources of Funds
$ %
Sponsor Equity          [REDACTED] [REDACTED]
New Debt            
Cash from Balance Sheet            
Total         $
3,780
100.0%  


Due Diligence

: The Proposal is subject to our completion of standard confirmatory diligence. Given our industry experience and the substantial preparatory work we have done, we can proceed expeditiously with the requisite due diligence and simultaneously negotiate a definitive agreement. Our work would include customary property-level diligence, financial diligence, and confirmatory legal, accounting and tax reviews. We have engaged [REDACTED] as our legal advisor in connection with the Proposal and are prepared to enter into a confidentiality agreement with you to facilitate these reviews. Given our and our advisors’ experience with transactions of this type, we expect to be able to complete the required due diligence and enter into definitive documentation within 45 days. A preliminary copy of our due diligence request list is attached as Appendix II to this letter. We are eager to commence work, and our team is available immediately.


Closing Conditions

: The consummation of the Transaction will be subject to limited customary closing conditions for a public company transaction of this nature.


Exclusivity

: We propose to enter into exclusive bilateral negotiations with you and work expeditiously to sign and announce the Transaction. We would expect the Transaction to provide for a customary “Go-Shop” period. A copy of our proposed exclusivity agreement is attached as Appendix III to this letter.


Reviews and Approvals

: This letter has been reviewed and approved by our investment committee.


Management and Founders

: We are impressed with the management team and prior to executing a definitive agreement, we would expect customary access to management to discuss their continuing roles. We are also happy, at the appropriate time, to discuss the Landy family’s goals and desires for future involvement with the Company, including continuing participation in the equity ownership of the Company.

This letter does not constitute a binding obligation or commitment of either party or its affiliates to proceed with any transaction. No such obligations will be imposed on either party or its affiliates unless and until a mutually acceptable definitive agreement is formally entered into by both parties.

We look forward to working collaboratively with the Board and its advisors to advance our Proposal. Please contact me at your earliest convenience to discuss next steps.

Sincerely,

/s/

Jason Aintabi

Appendix I

[FINANCIAL INSTITUTION ADDRESS]

12/01/2020

Blackwells Asset Management LLC

800 Third Avenue, 39th Floor
NY, NY 10022

Attention:
Mr. Jason Aintabi
Chief Investment Officer

Re: Acquisition Financing – Highly Confident Letter Ladies and Gentlemen:

You have informed [REDACTED] (“[REDACTED]”) that you are presently considering a transaction pursuant to which you and/or one or more of your affiliates (collectively, the “Sponsor”) would (i) acquire (the “Acquisition”), through a newly-formed corporation (“Newco”) wholly-owned by the Sponsor and other equity investors reasonably acceptable to [REDACTED] (collectively with the Sponsor, the “Equity Investors”), all or substantially all of the outstanding equity interests of, or all or substantially all of the business (including, without limitation, all assets, licenses and related operations) of, a company identified to us and code- named “[REDACTED]” (together with its subsidiaries, the “Acquired Business”) and (ii) refinance substantially all of the existing indebtedness of the Acquired Business and pay any and all accrued and unpaid interest and call premiums thereon (the “Refinancing”). We understand that the Acquired Business shall be acquired free of indebtedness and preferred stock, with such exceptions (if any) for any existing indebtedness as may be agreed to by [REDACTED].

[REDACTED] further understands that the sources of funds needed to effect the Acquisition and the Refinancing, to pay all fees and expenses incurred in connection with the Transaction (as defined below) and to provide for the working capital needs and general corporate purposes of Newco and its subsidiaries after giving effect to the Transaction shall be provided through:

(i) a cash common equity financing to be provided by the Equity Investors in an aggregate amount of not less than approximately 25% of the pro forma total consolidated capitalization of Newco and its subsidiaries after giving effect to the Transaction (the “Equity Financing”); and

(ii) third-party debt financing consisting of mortgage secured notes (the “Senior Mortgage Debt”) to be issued by Newco (either pursuant to a bridge financing or by private placement; all or a portion of the Senior Mortgage Debt may be in the form of an CMBS execution, and may include a mezzanine debt portion secured by equity pledges) in an aggregate principal amount of $2,640 million (the “Senior Acquisition Financing”)

The Acquisition, the Refinancing, the Equity Financing and the Senior Acquisition Financing collectively are herein called the “Transaction”.

[REDACTED] is pleased to inform you that, based on our preliminary review of certain financial information and projections provided by you to us, our understanding of the Transaction as described above and current market conditions and subject to the satisfaction of all conditions outlined below, we are highly confident in our ability to arrange and/or place the Senior Acquisition Financing (directly and/or through one or more of our affiliates) to finance, in part, the Transaction.

You understand and agree that our confidence in our ability to arrange and/or place the Senior Acquisition Financing is subject to, among other things, (i) there not having occurred any material adverse change in the condition (financial or otherwise), results of operations, business, assets, property, liabilities or prospects of the Acquired Business since the date of the most recent audited financial statements available on the date hereof for the Acquired Business, (ii) the terms and structure of the Senior Acquisition Financing and the Equity Financing being acceptable to [REDACTED], (iii) the negotiation, execution and delivery of documentation for each component of the Transaction and related transactions in form and substance satisfactory to [REDACTED], (iv) [REDACTED]’s and its representatives’ completion of and satisfaction with the results of their business and legal due diligence with respect to the Acquired Business and the Transaction, including, but not limited to, proposed business plans and projections and financial, accounting, environmental, tax, litigation, labor and pension matters, (v) the availability of audited and unaudited historical financial statements of the Acquired Business and pro forma financial statements of Newco and its subsidiaries after giving effect to the Transaction, in each case reasonably acceptable to [REDACTED] and in form and presentation as required by the Securities Act of 1933, as amended, and the rules and regulations thereunder applicable to registration statements filed thereunder, (vi) there not having been any disruption or material adverse change in the syndication market for credit facilities or the financial or capital markets in general, in the judgment of [REDACTED], (vii) [REDACTED] having been engaged to and having a reasonable time to arrange and market the Senior Acquisition Financing based on [REDACTED]’s experience in comparable transactions, (viii) satisfaction of all other conditions [REDACTED] would require to be fulfilled with respect to the Senior Acquisition Financing, and (ix) there is sufficient real estate collateral value that is free and clear of existing encumbrances and / or liens that would prevent the perfection of a mortgage security interest by the Senior Acquisition Financing.

You understand and agree that (i) we assume no responsibility for independently verifying any information provided to us in connection with our evaluation of the Transaction and that we have relied upon such information being complete and accurate in all material respects, (ii) this letter does not constitute a commitment on the part of, or engagement of, [REDACTED] or any of its affiliates to provide, arrange, place, underwrite and/or participate in any or all of the Senior Acquisition Financing or any other financing, on the terms described herein or otherwise, and that neither [REDACTED] nor any of its affiliates are under any obligation, as a result of this letter or otherwise, to provide or offer to provide any such commitment or engagement and (iii) [REDACTED] cannot make any commitments on behalf of any of its affiliates. Any commitment or engagement by [REDACTED] or any of its affiliates, if forthcoming, in respect of the Senior Acquisition Financing or any other financing would be evidenced by a separate written agreement executed by [REDACTED] (or a designated affiliate thereof) and would be subject to, among other things, (x) [REDACTED]’s and its representatives’ completion of and satisfaction with the results of their business and legal due diligence as outlined above, (y) [REDACTED]’s receipt of all credit, business selection, conflicts and other internal approvals of [REDACTED] and its relevant affiliates and our verification of all assumptions we have made and (z) the satisfaction of all conditions we would require to be fulfilled with respect thereto.

None of [REDACTED], any of its affiliates or any of their respective directors, officers, employees, representatives and agents shall be responsible or liable to you or any other person or entity for any damages or amounts of any kind or character which may be alleged as a result of this letter or the proposed Transaction, or any other transactions contemplated hereby. This letter is not intended to confer any benefits upon, or create any rights in favor of, any person or entity and may not be relied upon by any person or entity.

You acknowledge that (i) [REDACTED] may share with any of its affiliates, and such affiliates may share with [REDACTED], any information (including as relating to creditworthiness) related to the Transaction, the Sponsor, Newco or the Acquired Business (and each of their respective subsidiaries and affiliates), or any of the matters contemplated hereby and (ii) [REDACTED] and its affiliates may be providing debt financing, equity capital or other services (including financial advisory services) to other companies in respect of which you or the Acquired Business may have conflicting interests regarding the transactions described herein and otherwise. [REDACTED] agrees to treat, and cause any such affiliate to treat, all non-public information provided to it by you and the Acquired Business as confidential information in accordance with customary banking industry practices.

You agree that this letter is for your confidential use only and that, unless [REDACTED] has otherwise consented in writing, neither its existence nor the terms hereof will be disclosed by you to any person or entity other than (x) your officers, directors, employees, accountants, attorneys and other advisors and (y) the Acquired Business and its officers, directors, shareholders, employees, accountants, attorneys and other advisors, and then (in either case) only on a “need to know” basis in connection with the transactions contemplated hereby and on a confidential basis. Notwithstanding the foregoing, (i) you may file a copy of this letter in any public record in which it is required by law, in the opinion of your counsel, to be filed, and (ii) you may make such other public disclosure of the terms and conditions hereof as, and to the extent, you are required by law, in the opinion of your counsel, to make; provided that, in any such case, you shall provide written notification to [REDACTED] in advance of such disclosure.

We look forward to working with you to complete the proposed Transaction successfully.

Very truly yours,
[REDACTED]

About Blackwells Capital

Blackwells Capital was founded in 2016 by Jason Aintabi, its Chief Investment Officer. Since that time, it has made investments in public securities, engaging with management and boards, both publicly and privately, to help unlock value for stakeholders, including shareholders, employees and communities. Throughout their careers, Blackwells’ principals have invested globally on behalf of leading public and private equity firms and have held operating roles and served on the boards of media, energy, technology, insurance and real estate enterprises. For more information, please visit www.blackwellscap.com

Contact:

Gagnier Communications
Dan Gagnier / Jeffrey Mathews
646-569-5897
[email protected]

1 Market data as of 12/1/2020.
2 Balance sheet data as of 9/30/2020. Pro forma for issuance of 1.4 million units of Series C Preferred Stock.

 



Endeavour Increases its Stake in the Fetekro Project; Pre-Feasibility Study On Track for Q1-2021

ENDEAVOUR INCREASES ITS STAKE IN THE FETEKRO PROJECT;
PRE-FEASIBILITY STUDY ON TRACK FOR Q1-2021

Increased stake from 65% to 80%  ·  PFS to be based on 3Mtpa  ·  Mining permit process well underway

Abidjan, December 21, 2020 – Endeavour Mining (TSX:EDV) (OTCQX:EDVMF) is pleased to announce that it has increased its stake in the Fetekro Project in Côte d’Ivoire, ahead of a Pre-Feasibility Study (“PFS”) which is due to be published in Q1-2021.

Under the terms of the agreement, once the mining permit is granted, Endeavour will be entitled to an 80% stake in the Fetekro Project, compared to 65% currently, while SODEMI (the state-owned mining company) and the Government of Côte d’Ivoire will each have a 10% stake. Endeavour will retain the full ownership of the Fetekro exploration license until such time as it is converted into a mining license.

Sébastien de Montessus, President and CEO, commented:We are delighted to have concluded this agreement with our long-standing government partners, in a manner which allows all stakeholders to benefit from the value we expect to continue to unlock at Fetekro.

We believe that we have the opportunity to develop Fetekro into a cornerstone asset for Endeavour, which we define as assets with the potential to produce more than 200,000 ounces per annum over 10 years at low AISC.
Fetekro has
significant
exploration potential, an already defined large-scale deposit with straightforward metallurgy and high gold recovery. It also benefits from being located close to existing infrastructure and requires only minimal relocation.
We are eager to complete the PFS, which is expected to build on the PEA we recently published based on only half of the current resource, to demonstrate further the robust economics of the project.”

Endeavour acquired the additional stake from SODEMI for a consideration of $19 million plus contingent payments of $3 per ounce for future Proven and Probable reserves defined outside of the existing Measured and Indicated resource boundary. The contingent payment is based on a gold price of $1,450 per ounce and will be adjusted upwards or downwards in a linear relationship with the gold price.

ABOUT THE FETEKRO PROJECT

Located in north-central Côte d’Ivoire, within the northern end of the Oumé-Fetekro Greenstone Belt, the Fetekro Project is approximately 500km from Abidjan and close to existing infrastructure, including sealed roads and grid power.

Endeavour began exploration at Fetekro in March 2017, with the Lafigué deposit as the primary target. A maiden resource for Lafigué was published on October 29, 2018 and was updated on September 3, 2019 and again on August 18, 2020. As shown in Table 1 below, the latest resource update resulted in a 108% increase in Indicated resources to 2.5Moz at an average grade of 2.40 g/t Au.


Table 1: Lafigué Mineral Resource Estimate Evolution

  AS AT AUGUST 31, 2019   AS AT JULY 31, 2020 Δ
AU CONTENT
On a 100% basis Tonnage Grade Content   Tonnage Grade Content
(Mt) (Au g/t) (Au koz) (Mt) (Au g/t) (Au koz)
Measured Resource          
Indicated Resources 14.6 2.54 1,190   32.0 2.40 2,471 +108%
M&I Resources 14.6 2.54 1,190   32.0 2.40 2,471 +108%
Inferred Resources 0.9 2.17 60   0.8 2.52 66 +10%

Mineral Reserve Estimates follow the Canadian Institute of Mining, Metallurgy and Petroleum (“CIM”) definitions standards for mineral resources and reserves and have been completed in accordance with the Standards of Disclosure for Mineral Projects as defined by National Instrument 43-101. Reported tonnage and grade figures have been rounded from raw estimates to reflect the relative accuracy of the estimate. Minor variations may occur during the addition of rounded numbers. Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability. Resources were
constrained by MII Pit Shell and based on a cut-off of 0.5 g/t Au. For further details, please refer to Endeavour’s press release dated August 18, 2020, available on its website and on SEDAR under its profile.

A Preliminary Economic Assessment (“PEA”), based on the previous 1.2Moz Indicated resource, was published on August 18, 2020 and demonstrated robust project economics, as shown in Table 2 below.


Table 2: Initial PEA Highlights

  TOTAL LIFE OF MINE
Gold contained processed 1.0Moz
Average recovery rate 95%
Gold production 0.95Moz
Cash costs $592/oz
AISC $697/oz
Upfront capital cost $268m
Pre-tax NPV5% based $1,500/oz $372m
Pre-tax IRR based $1,500/oz 37%

For further information, please refer to Endeavour’s press release dated August 18, 2020, available on its website and on SEDAR under its profile.

A PFS is expected to be published in Q1-2021 and will be based on the updated 2.5Moz Indicated resource and will define a production scenario based on a 3.0Mtpa mill throughput (compared to 1.5Mtpa for the PEA). Given its strong exploration potential, Endeavour believes that Fetekro has the potential to become a cornerstone asset with a production target of +200koz per annum over 10 years at a low AISC.

The mining permitting process is well underway, with the environmental study completed and submitted. Receipt of the environmental permit is expected in early 2021, following which the exploitation license application will be submitted.

To date, only a small portion of the Fetekro property has been explored, as the priority has been the Lafigué deposit, which remains open at depth and along strike. Several additional exploration targets have been identified within 10km from Lafigué, which have had limited drilling of just 7,050 meters, as shown in Figure 1 below.


Figure 1: Fetekro Map with Exploration Targets


 

The current 15,000 meter drilling campaign is expected to be completed during Q4-2020, with the aim of further extending the Fetekro resource and testing nearby targets, including Lafigué Sud, as shown in Figure 2 below.


Figure 2: Q4-2020 Fetekro Drilling Campaign  


 

QUALIFIED PERSONS

The scientific and technical content of this news release has been reviewed, verified and compiled by Silvia Bottero, Professional Natural Scientist, VP Exploration Côte d’Ivoire for Endeavour. Silvia Bottero has more than 18 years of mineral exploration and mining experience and is a “Qualified Person” as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).  

CONTACT
INFORMATION

Martino De Ciccio

VP – Strategy & Investor Relations
+44 203 640 8665
[email protected]

Brunswick Group LLP in London

Carole Cable, Partner
+44 7974 982 458
[email protected]

  Vincic Advisors in Toronto

John Vincic, Principal

+1 (647) 402 6375
[email protected]

ABOUT ENDEAVOUR
MINING
CORPORATION

Endeavour Mining is a multi-asset gold producer focused on West Africa, with two mines (Ity and Agbaou) in Côte d’Ivoire, four mines (Houndé, Mana, Karma and Boungou) in Burkina Faso, four potential development projects (Fetekro, Kalana, Bantou and Nabanga) and a strong portfolio of exploration assets on the highly prospective Birimian Greenstone Belt across Burkina Faso, Côte d’Ivoire, Mali and Guinea.   

As a leading gold producer, Endeavour Mining is committed to principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is listed on the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit


www.endeavourmining.com


.

Corporate Office: 5 Young St, Kensington, London W8 5EH, UK   

This news release contains “forward-looking statements” including but not limited to, statements with respect to Endeavour’s plans and operating performance, the estimation of mineral reserves and resources, the timing and amount of estimated future production, costs of future production, future capital expenditures, and the success of exploration activities. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects”, “expected”, “budgeted”, “forecasts”, and “anticipates”. Forward-looking statements, while based on management’s best estimates and assumptions, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the successful integration of acquisitions; risks related to international operations; risks related to general economic conditions and credit availability, actual results of current exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates, increases in market prices of mining consumables, possible variations in ore reserves, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of development or construction activities, changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Endeavour operates. Although Endeavour has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Please refer to Endeavour’s most recent Annual Information Form filed under its profile at www.sedar.com for further information respecting the risks affecting Endeavour and its business. AISC, all-in sustaining costs at the mine level, cash costs, operating EBITDA, all-in sustaining margin, free cash flow, net free cash flow, free cash flow per share, net debt, and adjusted earnings are non-GAAP financial performance measures with no standard meaning under IFRS, further discussed in the section Non-GAAP Measures in the most recently filed Management Discussion and Analysis.

Attachment